Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

NCT01376713 | Completed Phase 2 DMC

• 1 other identifier: EudraCT: 2010-023277-19
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to assess the overall disease control rate of Ofatumumab wo/w Dacarbazine in subjects with American Joint Committee on Cancer (AJCC 2009) unresectable stage III or stage IV melanoma.

Conditions

Stage III Melanoma; Stage IV Melanoma

Keywords

Melanoma

Outcome Measures

Primary Outcomes (1)

• Disease control according to RECIST v. 1.1 criteria

  Disease control according to RECIST v. 1.1 criteria until week 24

  24 weeks

Secondary Outcomes (4)

• Assessment of progression-free survival (PFS)

  approximately 2 years

• Evaluation of cell biological responses

  From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 weeks

• Duration of disease control

  approximately 2 years

• Overall survival

  approximately 2 years

Study Arms (2)

Ofatumumab alone

EXPERIMENTAL

Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).

Biological: Ofatumumab

Ofatumumab plus Dacarbazine

EXPERIMENTAL

Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.

Biological: Ofatumumab plus Dacarbazine

Interventions

Ofatumumab BIOLOGICAL

Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks

Also known as: Arzerra

Ofatumumab alone

Ofatumumab plus Dacarbazine BIOLOGICAL

Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks.

Also known as: Arzerra, DTIC

Ofatumumab plus Dacarbazine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients older than 18 years
• Signed informed consent
• Metastatic non-ocular melanoma - unresectable stage III B (T1- 4a, N2b-c), stage III C (AJCC 2009) or stage IV (AJCC 2009).
• measurable disease with more than one metastatic lesion, according to RECIST v. 1.1 criteria,
• One of these metastases must be resectable prior to anti-CD20 therapy.
• ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.
• As soon as BRAF or other kinase inhibitors are standard of care, we will include only patients who cannot be considered for those therapies. E.g. patients with tumors not carrying the respective mutational profile, patients refusing this kind of therapy for any reason, patients being not eligible to those therapies due to contraindications or disease progression under such kind of therapy.
• Life expectancy of 3 month or longer
• Negative pregnancy test in female patients of childbearing potential and adequate contraception in female patients of childbearing age.

You may not qualify if:

• Patients with active brain metastasis (exception: brain metastases being stable with and without corticosteroids for 2 months after treatment by surgery or radiation therapy) and immunoglobulin-deficiency will be excluded.
• Subjects meeting any of the following criteria must not be enrolled in an ofatumumab study:
• Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
• Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
• Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
• Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C.
• History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
• HIV positive
• Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to enrollment, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
• Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.
• Positive serology for hepatitis C (HC) defined as a positive test for HCAb (HC antibodies), in which case reflexively perform a HC RIBA (recombinant immunoblot assay) on the same sample to confirm the result
• Screening laboratory values:
• hemoglobin \< 8g/dL platelets \<70 x 109/L leukocytes \<1.5 x 109/L creatinine \>2.0 times ULN (upper limit of normal) total bilirubin \>1.5 times ULN liver transaminase ALT \>2.5 times ULN alkaline phosphatase \>2.5 times ULN
• Pregnant or lactating women
• Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy

Sponsors & Collaborators

• Medical University of Vienna: lead

Study Sites (2)

Rudolfstiftung

Vienna, 1030, Austria

Location

Medical University of Vienna

Vienna, 1090, Austria

Location

Related Publications (1)

• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.

  PMID: 19917835 BACKGROUND

MeSH Terms

Conditions

Melanoma

Interventions

ofatumumab; Dacarbazine

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Stephan N Wagner, MD

  Medical University of Vienna

  PRINCIPAL INVESTIGATOR

• Klemens Rappersberger, Prof. Dr.

  Hospital Rudolfstiftung

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: June 16, 2011
• First Posted: June 20, 2011
• Study Start: June 1, 2011
• Primary Completion: January 1, 2015
• Study Completion: May 1, 2015
• Last Updated: October 6, 2015

Record last verified: 2015-10

Locations

AU (2)